Get the Stockscreener App
3.68
2.79%
0.10
Pre-market:
3.77
0.09
+2.45%
Artiva Biotherapeutics Inc stock is traded at $3.68, with a volume of 38,868.
It is up +2.79% in the last 24 hours and up +2.51% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$3.58
Open:
$3.55
24h Volume:
38,868
Relative Volume:
0.02
Market Cap:
$90.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.79%
1M Performance:
+2.51%
6M Performance:
+86.80%
1Y Performance:
-71.07%
1-Day Range:
$3.51
$3.69
1-Week Range:
$3.28
$3.78
52-Week Range:
$1.47
$13.14
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
3.68 | 87.87M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
How Artiva Biotherapeutics Inc. stock trades before earningsPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - Newser
Will Artiva Biotherapeutics Inc. stock outperform tech sector in 2025Trade Exit Report & Consistent Profit Trading Strategies - Newser
Risk Hedge: Can Artiva Biotherapeutics Inc. stock rebound after recent weakness2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
Can Artiva Biotherapeutics Inc. stock rebound after recent weaknessDividend Hike & Free Technical Confirmation Trade Alerts - BỘ NỘI VỤ
Will Artiva Biotherapeutics Inc. stock gain from lower inflationJuly 2025 Summary & Safe Capital Growth Trade Ideas - moha.gov.vn
A new trading data show Allarity Therapeutics Inc (ALLR) is showing positive returns. - Setenews
Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $19.00 - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Artiva Biotherapeutics Inc. stock is seen as undervalued2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Will Artiva Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
How resilient is Artiva Biotherapeutics Inc. stock in market downturnsWeekly Investment Report & Expert Curated Trade Ideas - newser.com
Is Artiva Biotherapeutics Inc. stock attractive for retirement portfoliosWeekly Market Report & Weekly Consistent Profit Watchlists - newser.com
Why Artiva Biotherapeutics Inc. stock could rally in 2025 - newser.com
Artiva Biotherapeutics Inc. stock daily chart insights2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Is Artiva Biotherapeutics Inc. stock supported by strong cash flows2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
ARTV: Off-the-shelf NK cell therapy for autoimmune disease advances toward pivotal RA trial with strong safety and funding - TradingView
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 By Investing.com - Investing.com UK
Relative strength of Artiva Biotherapeutics Inc. in sector analysisSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 - Investing.com India
Artiva Biotherapeutics Reports Positive AlloNK Trial Results - MSN
Equities Analysts Offer Predictions for ARTV FY2025 Earnings - Defense World
Why Artiva Biotherapeutics Inc. stock is popular among millennialsPortfolio Update Summary & Real-Time Volume Analysis - newser.com
How to escape a deep drawdown in Artiva Biotherapeutics Inc.Quarterly Profit Review & High Accuracy Swing Entry Alerts - newser.com
Can Artiva Biotherapeutics Inc. stock resist sector downturnsQuarterly Earnings Summary & Verified Swing Trading Watchlist - newser.com
What risks investors should watch in Artiva Biotherapeutics Inc. stock2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
Published on: 2025-11-14 18:41:04 - newser.com
Why analysts remain bullish on Artiva Biotherapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - newser.com
HC Wainwright Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock - Defense World
Identifying reversal signals in Artiva Biotherapeutics Inc.2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development - TipRanks
HC Wainwright & Co. Maintains Artiva Biotherapeutics (ARTV) Buy Recommendation - Nasdaq
Promising Developments in Artiva Biotherapeutics’ AlloNK Therapy for Autoimmune Diseases - TipRanks
Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge - TipRanks
Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results - TipRanks
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):